Patents by Inventor Kim Tang
Kim Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11980211Abstract: The use of verbascoside or a related compound thereof to enhance the sweetness of a sweetness modifier and to decrease the amount of a sweetness modifier used in a consumable is provided.Type: GrantFiled: July 12, 2019Date of Patent: May 14, 2024Assignee: International Flavors & FragrancesInventors: Ajay Pratap Singh, Hassan Mustaq Ubaideen, Jung-A Kim, Xiao-Qing Tang, Hsi-Wen Chin, Michelle Eve Huber, Xiaodong Li, Thumpalasseril V. John
-
Publication number: 20240117356Abstract: The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK.Type: ApplicationFiled: December 30, 2021Publication date: April 11, 2024Applicant: Dyne Therapeutics, Inc.Inventors: Romesh R. Subramanian, Timothy Weeden, Cody A. Waltham, Stefano Zanotti, Kim Tang, Mohammed T. Qatanani, Brendan Quinn, John Najim
-
Patent number: 11948224Abstract: One embodiment provides an apparatus comprising a memory stack including multiple memory dies and a parallel processor including a plurality of multiprocessors. Each multiprocessor has a single instruction, multiple thread (SIMT) architecture, the parallel processor coupled to the memory stack via one or more memory interfaces. At least one multiprocessor comprises a multiply-accumulate circuit to perform multiply-accumulate operations on matrix data in a stage of a neural network implementation to produce a result matrix comprising a plurality of matrix data elements at a first precision, precision tracking logic to evaluate metrics associated with the matrix data elements and indicate if an optimization is to be performed for representing data at a second stage of the neural network implementation, and a numerical transform unit to dynamically perform a numerical transform operation on the matrix data elements based on the indication to produce transformed matrix data elements at a second precision.Type: GrantFiled: November 1, 2022Date of Patent: April 2, 2024Assignee: Intel CorporationInventors: Elmoustapha Ould-Ahmed-Vall, Sara S. Baghsorkhi, Anbang Yao, Kevin Nealis, Xiaoming Chen, Altug Koker, Abhishek R. Appu, John C. Weast, Mike B. Macpherson, Dukhwan Kim, Linda L. Hurd, Ben J. Ashbaugh, Barath Lakshmanan, Liwei Ma, Joydeep Ray, Ping T. Tang, Michael S. Strickland
-
Patent number: 11931421Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).Type: GrantFiled: April 19, 2023Date of Patent: March 19, 2024Assignee: Dyne Therapeutics, Inc.Inventors: Scott Hilderbrand, Timothy Weeden, John Najim, Stefano Zanotti, Romesh R. Subramanian, Mohammed T. Qatanani, Cody A. Desjardins, Kim Tang, Brendan Quinn
-
Publication number: 20230381153Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.Type: ApplicationFiled: May 12, 2023Publication date: November 30, 2023Inventors: Joon Jung, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Nicholas Robert Perl, Peter Germano, Maria D. Ribadeneira, Kim Tang
-
Publication number: 20230330247Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).Type: ApplicationFiled: April 19, 2023Publication date: October 19, 2023Applicant: Dyne Therapeutics, Inc.Inventors: Scott Hilderbrand, Timothy Weeden, John Najim, Stefano Zanotti, Romesh R. Subramanian, Mohammed T. Qatanani, Cody A. Desjardins, Kim Tang, Brendan Quinn
-
Patent number: 11731977Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: GrantFiled: September 27, 2021Date of Patent: August 22, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Paul Allan Renhowe, Joon Jung, Kim Tang
-
Patent number: 11690828Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.Type: GrantFiled: November 7, 2017Date of Patent: July 4, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Joon Jung, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Nicholas Robert Perl, Peter Germano, Maria D. Ribadeneira, Kim Tang
-
Publication number: 20220017515Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable.Type: ApplicationFiled: September 27, 2021Publication date: January 20, 2022Inventors: Glen Robert Rennie, Timothy Claude Barden, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Takashi Nakai, Ara Mermerian, Lei Jia, Karthik Iyer, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Kim Tang
-
Publication number: 20220009937Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Paul Allan Renhowe, Joon Jung, Kim Tang
-
Patent number: 11180493Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).Type: GrantFiled: November 7, 2017Date of Patent: November 23, 2021Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Timothy Claude Barden, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Takashi Nakai, Ara Mermerian, Lei Jia, Karthik Iyer, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Kim Tang
-
Publication number: 20210087198Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Paul Allan Renhowe, Joon Jung, Kim Tang
-
Patent number: 10858363Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: GrantFiled: February 12, 2019Date of Patent: December 8, 2020Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Takashi Nakai, Ara Mermerian, Lei Jia, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Karthik Iyer, Timothy Claude Barden, Kim Tang
-
Publication number: 20200071318Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).Type: ApplicationFiled: November 7, 2017Publication date: March 5, 2020Inventors: Glen Robert Rennie, Timothy Claude Barden, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Takashi Nakai, Ara Mermerian, Lei Jia, Karthik Iyer, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Kim Tang
-
Publication number: 20190343813Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.Type: ApplicationFiled: November 7, 2017Publication date: November 14, 2019Applicant: Cyclerion Therapeutics, Inc.Inventors: Joon Jung, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Nicholas Robert Perl, Peter Germano, Maria D. Ribadeneira, Kim Tang
-
Publication number: 20190248794Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: ApplicationFiled: February 12, 2019Publication date: August 15, 2019Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Takashi Nakai, Ara Mermerian, Lei Jia, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Karthik Iyer, Timothy Claude Barden, Kim Tang
-
Publication number: 20180065971Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: ApplicationFiled: September 1, 2017Publication date: March 8, 2018Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Takashi Nakai, Ara Mermerian, James Jia, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Karthik Iyer, Timothy Claude Barden, Kim Tang
-
Publication number: 20070287309Abstract: A connector, such as an edge card connector, is provided with positive locking ejection latches. The positive locking of the ejection latches ensure that an associated card inserted into the connector will not accidentally be ejected under shock and vibration conditions. To use the ejection latches, a locking member provided in association with the ejections latches must be disabled.Type: ApplicationFiled: June 8, 2006Publication date: December 13, 2007Inventors: James McGrath, Kim Tang, Ramesh Rao